PMC 401
Alternative Names: PMC-401Latest Information Update: 03 Nov 2022
At a glance
- Originator PharmAbcine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; Angiopoietin-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Sep 2022 Preclinical trials in Cancer in South Korea (Parenteral) (PharmAbcine pipeline) (Before September 2022)